Physician profile
Nicholas Ray Kalman
NPI 1538548748
$535.14
in general payments reported to CMS, 2019-2025
10 companies · $43.07 in 2025
The $43.07 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $29.85 · 2021: $122 · 2022: $46.98 · 2023: $28.39 · 2024: $62.15 · 2025: $43.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $133.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $122.16 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $120.29 | 2019-2025 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.59 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $60.38 | 2019-2020 | |
| Pfizer INC. | $29.63 | 2019-2024 | |
| Abbott Laboratories | $21.51 | 2025 | Eterna |
| Supernus Pharmaceuticals, INC. | $18.62 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.34 | 2019 | |
| Merck Sharp & Dohme LLC | $16.83 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Kalman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.